{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:44:13Z","timestamp":1781246653143,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.kint.2023.03.037","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T04:23:47Z","timestamp":1682655827000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials"],"prefix":"10.1016","volume":"104","author":[{"given":"Hiddo J.L.","family":"Heerspink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Jongs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schloemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.03.037_bib1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.03.037_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in Collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.03.037_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2013.09.016","volume":"63","author":"Heerspink","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.03.037_bib4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an endpoint for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug and Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.03.037_bib5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.kint.2020.07.013","article-title":"International consensus definitions of clinical trial outcomes for kidney failure: 2020","volume":"98","author":"Levin","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.03.037_bib6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/j.ajkd.2014.08.017","article-title":"GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials","volume":"64","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.03.037_bib7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.03.037_bib8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.03.037_bib9","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.03.037_bib10","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.03.037_bib11","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.03.037_bib12","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/sim.8282","article-title":"Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease","volume":"38","author":"Vonesh","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2023.03.037_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/biom.13438","article-title":"Biased estimation with shared parameter models in the presence of competing dropout mechanisms","volume":"78","author":"Vonesh","year":"2022","journal-title":"Biometrics"},{"key":"10.1016\/j.kint.2023.03.037_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2021070948","article-title":"Acute treatment effects on GFR in randomized clinical trials of kidney disease progression","volume":"33","author":"Neuen","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.03.037_bib15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1053\/j.ajkd.2014.08.019","article-title":"Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study","volume":"64","author":"Greene","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.03.037_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2023.03.037_bib17","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/ndt\/gfm364","article-title":"Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease","volume":"22","author":"Dhaun","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.03.037_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MNH.0000000000000716","article-title":"Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease","volume":"30","author":"Smeijer","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2023.03.037_bib19","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/ndt\/gfz179","article-title":"Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME(R) trial","volume":"35","author":"Perkovic","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.03.037_bib20","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1681\/ASN.2019121312","article-title":"Different eGFR decline thresholds and renal effects of canagliflozin: data from the CANVAS Program","volume":"31","author":"Oshima","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.03.037_bib21","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2023.03.037_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.03.037_bib23","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.03.037_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.03.037_bib25","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823003095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823003095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:05:00Z","timestamp":1758762300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823003095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0085253823003095"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.03.037","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}